Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 74

1.

Sialic Acid-Engineered IL4-10 Fusion Protein is Bioactive and Rapidly Cleared from the Circulation.

Steen-Louws C, Boross P, Prado J, Meeldijk J, Langenhorst JB, Huitema ADR, den Hartog MT, Boon L, Lafeber FPJG, Hack CE, Eijkelkamp N, Popov-Celeketic J.

Pharm Res. 2019 Dec 26;37(2):17. doi: 10.1007/s11095-019-2744-y.

2.

Heparin Forms Polymers with Cell-free DNA Which Elongate Under Shear in Flowing Blood.

de Vries JC, Barendrecht AD, Clark CC, Urbanus RT, Boross P, de Maat S, Maas C.

Sci Rep. 2019 Dec 4;9(1):18316. doi: 10.1038/s41598-019-54818-3.

3.

New insights in Type I and II CD20 antibody mechanisms-of-action with a panel of novel CD20 antibodies.

Meyer S, Evers M, Jansen JHM, Buijs J, Broek B, Reitsma SE, Moerer P, Amini M, Kretschmer A, Ten Broeke T, den Hartog MT, Rijke M, Klein C, Valerius T, Boross P, Leusen JHW.

Br J Haematol. 2018 Mar;180(6):808-820. doi: 10.1111/bjh.15132. Epub 2018 Feb 22.

PMID:
29468712
4.

Valley-enhanced fast relaxation of gate-controlled donor qubits in silicon.

Boross P, Széchenyi G, Pályi A.

Nanotechnology. 2016 Aug 5;27(31):314002. doi: 10.1088/0957-4484/27/31/314002. Epub 2016 Jun 23.

PMID:
27334425
5.

The Therapeutic CD38 Monoclonal Antibody Daratumumab Induces Programmed Cell Death via Fcγ Receptor-Mediated Cross-Linking.

Overdijk MB, Jansen JH, Nederend M, Lammerts van Bueren JJ, Groen RW, Parren PW, Leusen JH, Boross P.

J Immunol. 2016 Aug 1;197(3):807-13. doi: 10.4049/jimmunol.1501351. Epub 2016 Jun 17.

6.

Improved in vivo anti-tumor effects of IgA-Her2 antibodies through half-life extension and serum exposure enhancement by FcRn targeting.

Meyer S, Nederend M, Jansen JH, Reiding KR, Jacobino SR, Meeldijk J, Bovenschen N, Wuhrer M, Valerius T, Ubink R, Boross P, Rouwendal G, Leusen JH.

MAbs. 2016;8(1):87-98. doi: 10.1080/19420862.2015.1106658. Epub 2015 Oct 14. Erratum in: MAbs. 2017 Jan;9(1):165.

7.

A comparison of anti-HER2 IgA and IgG1 in vivo efficacy is facilitated by high N-glycan sialylation of the IgA.

Rouwendal GJ, van der Lee MM, Meyer S, Reiding KR, Schouten J, de Roo G, Egging DF, Leusen JH, Boross P, Wuhrer M, Verheijden GF, Dokter WH, Timmers M, Ubink R.

MAbs. 2016;8(1):74-86. doi: 10.1080/19420862.2015.1102812. Epub 2015 Oct 6.

8.

Simultaneous Targeting of FcγRs and FcαRI Enhances Tumor Cell Killing.

Brandsma AM, Ten Broeke T, Nederend M, Meulenbroek LA, van Tetering G, Meyer S, Jansen JH, Beltrán Buitrago MA, Nagelkerke SQ, Németh I, Ubink R, Rouwendal G, Lohse S, Valerius T, Leusen JH, Boross P.

Cancer Immunol Res. 2015 Dec;3(12):1316-24. doi: 10.1158/2326-6066.CIR-15-0099-T. Epub 2015 Sep 25.

9.

Regulation of complement and modulation of its activity in monoclonal antibody therapy of cancer.

Meyer S, Leusen JH, Boross P.

MAbs. 2014;6(5):1133-44. doi: 10.4161/mabs.29670. Epub 2014 Oct 30. Review.

10.

FcRγ-chain ITAM signaling is critically required for cross-presentation of soluble antibody-antigen complexes by dendritic cells.

Boross P, van Montfoort N, Stapels DA, van der Poel CE, Bertens C, Meeldijk J, Jansen JH, Verbeek JS, Ossendorp F, Wubbolts R, Leusen JH.

J Immunol. 2014 Dec 1;193(11):5506-14. doi: 10.4049/jimmunol.1302012. Epub 2014 Oct 29.

11.

A novel FcγRIIa Q27W gene variant is associated with common variable immune deficiency through defective FcγRIIa downstream signaling.

Flinsenberg TW, Janssen WJ, Herczenik E, Boross P, Nederend M, Jongeneel LH, Scholman RC, Boelens JJ, Maas C, van Gijn ME, van Montfrans JM, Leusen JH, Boes M.

Clin Immunol. 2014 Nov;155(1):108-17. doi: 10.1016/j.clim.2014.09.006. Epub 2014 Sep 19.

PMID:
25242138
12.

FcγRIIb on myeloid cells rather than on B cells protects from collagen-induced arthritis.

Yilmaz-Elis AS, Ramirez JM, Asmawidjaja P, van der Kaa J, Mus AM, Brem MD, Claassens JW, Breukel C, Brouwers C, Mangsbo SM, Boross P, Lubberts E, Verbeek JS.

J Immunol. 2014 Jun 15;192(12):5540-7. doi: 10.4049/jimmunol.1303272. Epub 2014 May 19.

13.

Anti-tumor activity of human IgG1 anti-gp75 TA99 mAb against B16F10 melanoma in human FcgammaRI transgenic mice.

Boross P, Jansen JH, van Tetering G, Nederend M, Brandsma A, Meyer S, Torfs E, van den Ham HJ, Meulenbroek L, de Haij S, Leusen JH.

Immunol Lett. 2014 Aug;160(2):151-7. doi: 10.1016/j.imlet.2014.02.005. Epub 2014 Mar 5.

PMID:
24613852
14.

Effect of a tail piece cysteine deletion on biochemical and functional properties of an epidermal growth factor receptor-directed IgA2m(1) antibody.

Brunke C, Lohse S, Derer S, Peipp M, Boross P, Kellner C, Beyer T, Dechant M, Royle L, Liew LP, Leusen JH, Valerius T.

MAbs. 2013 Nov-Dec;5(6):936-45. doi: 10.4161/mabs.26396.

15.

A unified theory of spin-relaxation due to spin-orbit coupling in metals and semiconductors.

Boross P, Dóra B, Kiss A, Simon F.

Sci Rep. 2013 Nov 20;3:3233. doi: 10.1038/srep03233.

16.

Inhibition of the classical and lectin pathway of the complement system by recombinant LAIR-2.

Olde Nordkamp MJ, Boross P, Yildiz C, Jansen JH, Leusen JH, Wouters D, Urbanus RT, Hack CE, Meyaard L.

J Innate Immun. 2014;6(3):284-92. doi: 10.1159/000354976. Epub 2013 Nov 1.

17.

Immunotherapy targeting inhibitory Fcγ receptor IIB (CD32b) in the mouse is limited by monoclonal antibody consumption and receptor internalization.

Williams EL, Tutt AL, Beers SA, French RR, Chan CH, Cox KL, Roghanian A, Penfold CA, Butts CL, Boross P, Verbeek JS, Cragg MS, Glennie MJ.

J Immunol. 2013 Oct 15;191(8):4130-40. doi: 10.4049/jimmunol.1301430. Epub 2013 Sep 11.

18.

IgA EGFR antibodies mediate tumour killing in vivo.

Boross P, Lohse S, Nederend M, Jansen JH, van Tetering G, Dechant M, Peipp M, Royle L, Liew LP, Boon L, van Rooijen N, Bleeker WK, Parren PW, van de Winkel JG, Valerius T, Leusen JH.

EMBO Mol Med. 2013 Aug;5(8):1213-26. doi: 10.1002/emmm.201201929.

19.

Identification of a novel CD40 ligand for targeted imaging of inflammatory plaques by phage display.

Yu H, Segers F, Sliedregt-Bol K, Bot I, Woltman AM, Boross P, Verbeek S, Overkleeft H, van der Marel GA, van Kooten C, van Berkel TJ, Biessen EA.

FASEB J. 2013 Oct;27(10):4136-46. doi: 10.1096/fj.12-224667. Epub 2013 Jul 29.

PMID:
23896727
20.

Staphylococcus aureus formyl peptide receptor-like 1 inhibitor (FLIPr) and its homologue FLIPr-like are potent FcγR antagonists that inhibit IgG-mediated effector functions.

Stemerding AM, Köhl J, Pandey MK, Kuipers A, Leusen JH, Boross P, Nederend M, Vidarsson G, Weersink AY, van de Winkel JG, van Kessel KP, van Strijp JA.

J Immunol. 2013 Jul 1;191(1):353-62. doi: 10.4049/jimmunol.1203243. Epub 2013 Jun 5.

21.

Mechanisms of action of CD20 antibodies.

Boross P, Leusen JH.

Am J Cancer Res. 2012;2(6):676-90. Epub 2012 Nov 20.

22.

FcγRIIb on myeloid cells and intrinsic renal cells rather than B cells protects from nephrotoxic nephritis.

Sharp PE, Martin-Ramirez J, Mangsbo SM, Boross P, Pusey CD, Touw IP, Cook HT, Verbeek JS, Tarzi RM.

J Immunol. 2013 Jan 1;190(1):340-8. doi: 10.4049/jimmunol.1202250. Epub 2012 Nov 30.

23.

Boosting antibody therapy with complement.

Boross P, Leusen JH.

Blood. 2012 Jun 21;119(25):5945-7. doi: 10.1182/blood-2012-04-420760.

PMID:
22730521
24.

Characterization of a mutated IgA2 antibody of the m(1) allotype against the epidermal growth factor receptor for the recruitment of monocytes and macrophages.

Lohse S, Brunke C, Derer S, Peipp M, Boross P, Kellner C, Beyer T, Dechant M, van der Winkel JG, Leusen JH, Valerius T.

J Biol Chem. 2012 Jul 20;287(30):25139-50. doi: 10.1074/jbc.M112.353060. Epub 2012 Jun 7.

25.

Fcγ receptor IIb strongly regulates Fcγ receptor-facilitated T cell activation by dendritic cells.

van Montfoort N, 't Hoen PA, Mangsbo SM, Camps MG, Boross P, Melief CJ, Ossendorp F, Verbeek JS.

J Immunol. 2012 Jul 1;189(1):92-101. doi: 10.4049/jimmunol.1103703. Epub 2012 May 30.

26.

Quantitative analysis of proteins in the tear fluid of patients with diabetic retinopathy.

Csősz É, Boross P, Csutak A, Berta A, Tóth F, Póliska S, Török Z, Tőzsér J.

J Proteomics. 2012 Apr 3;75(7):2196-204. doi: 10.1016/j.jprot.2012.01.019. Epub 2012 Jan 26.

PMID:
22300579
27.

Both activating and inhibitory Fc gamma receptors mediate rituximab-induced trogocytosis of CD20 in mice.

Boross P, Jansen JH, Pastula A, van der Poel CE, Leusen JH.

Immunol Lett. 2012 Mar 30;143(1):44-52. doi: 10.1016/j.imlet.2012.01.004. Epub 2012 Jan 23.

PMID:
22285696
28.

Increased incidence of anti-GBM disease in Fcgamma receptor 2b deficient mice, but not mice with conditional deletion of Fcgr2b on either B cells or myeloid cells alone.

Sharp PE, Martin-Ramirez J, Boross P, Mangsbo SM, Reynolds J, Moss J, Pusey CD, Cook HT, Tarzi RM, Verbeek JS.

Mol Immunol. 2012 Feb;50(1-2):49-56. doi: 10.1016/j.molimm.2011.12.007. Epub 2012 Jan 14.

PMID:
22244885
29.

Critical differences in HIV-1 and HIV-2 protease specificity for clinical inhibitors.

Tie Y, Wang YF, Boross PI, Chiu TY, Ghosh AK, Tozser J, Louis JM, Harrison RW, Weber IT.

Protein Sci. 2012 Mar;21(3):339-50. doi: 10.1002/pro.2019. Epub 2012 Jan 24.

30.

The in vivo mechanism of action of CD20 monoclonal antibodies depends on local tumor burden.

Boross P, Jansen JH, de Haij S, Beurskens FJ, van der Poel CE, Bevaart L, Nederend M, Golay J, van de Winkel JG, Parren PW, Leusen JH.

Haematologica. 2011 Dec;96(12):1822-30. doi: 10.3324/haematol.2011.047159. Epub 2011 Aug 31.

31.

The inhibiting Fc receptor for IgG, FcγRIIB, is a modifier of autoimmune susceptibility.

Boross P, Arandhara VL, Martin-Ramirez J, Santiago-Raber ML, Carlucci F, Flierman R, van der Kaa J, Breukel C, Claassens JW, Camps M, Lubberts E, Salvatori D, Rastaldi MP, Ossendorp F, Daha MR, Cook HT, Izui S, Botto M, Verbeek JS.

J Immunol. 2011 Aug 1;187(3):1304-13. doi: 10.4049/jimmunol.1101194. Epub 2011 Jul 1.

32.

Cytokine-induced immune complex binding to the high-affinity IgG receptor, FcγRI, in the presence of monomeric IgG.

van der Poel CE, Karssemeijer RA, Boross P, van der Linden JA, Blokland M, van de Winkel JG, Leusen JH.

Blood. 2010 Dec 9;116(24):5327-33. doi: 10.1182/blood-2010-04-280214. Epub 2010 Aug 30.

PMID:
20805361
33.

In vivo cytotoxicity of type I CD20 antibodies critically depends on Fc receptor ITAM signaling.

de Haij S, Jansen JH, Boross P, Beurskens FJ, Bakema JE, Bos DL, Martens A, Verbeek JS, Parren PW, van de Winkel JG, Leusen JH.

Cancer Res. 2010 Apr 15;70(8):3209-17. doi: 10.1158/0008-5472.CAN-09-4109. Epub 2010 Mar 30.

34.

Highly B lymphocyte-specific tamoxifen inducible transgene expression of CreER T2 by using the LC-1 locus BAC vector.

Boross P, Breukel C, van Loo PF, van der Kaa J, Claassens JW, Bujard H, Schönig K, Verbeek JS.

Genesis. 2009 Nov;47(11):729-35. doi: 10.1002/dvg.20549.

PMID:
19621440
35.

Drug targets in human T-lymphotropic virus type 1 (HTLV-1) infection.

Boross P, Bagossi P, Weber IT, Tözsér J.

Infect Disord Drug Targets. 2009 Apr;9(2):159-71. Review.

PMID:
19275704
36.

Amino acid preferences of retroviral proteases for amino-terminal positions in a type 1 cleavage site.

Eizert H, Bander P, Bagossi P, Sperka T, Miklóssy G, Boross P, Weber IT, Tözsér J.

J Virol. 2008 Oct;82(20):10111-7. doi: 10.1128/JVI.00418-08. Epub 2008 Aug 13.

37.

C-terminal residues of mature human T-lymphotropic virus type 1 protease are critical for dimerization and catalytic activity.

Kádas J, Boross P, Weber IT, Bagossi P, Matúz K, Tözsér J.

Biochem J. 2008 Dec 15;416(3):357-64. doi: 10.1042/BJ20071132.

38.

Destructive arthritis in the absence of both FcgammaRI and FcgammaRIII.

Boross P, van Lent PL, Martin-Ramirez J, van der Kaa J, Mulder MH, Claassens JW, van den Berg WB, Arandhara VL, Verbeek JS.

J Immunol. 2008 Apr 1;180(7):5083-91.

39.

Potent new antiviral compound shows similar inhibition and structural interactions with drug resistant mutants and wild type HIV-1 protease.

Wang YF, Tie Y, Boross PI, Tozser J, Ghosh AK, Harrison RW, Weber IT.

J Med Chem. 2007 Sep 6;50(18):4509-15. Epub 2007 Aug 16.

40.

HIV-1 protease dimer interface mutations that compensate for viral reverse transcriptase instability in infectious virions.

Olivares I, Mulky A, Boross PI, Tözsér J, Kappes JC, López-Galíndez C, Menéndez-Arias L.

J Mol Biol. 2007 Sep 14;372(2):369-81. Epub 2007 Jul 3.

41.

Bovine leukemia virus protease: comparison with human T-lymphotropic virus and human immunodeficiency virus proteases.

Sperka T, Miklóssy G, Tie Y, Bagossi P, Zahuczky G, Boross P, Matúz K, Harrison RW, Weber IT, Tözsér J.

J Gen Virol. 2007 Jul;88(Pt 7):2052-63.

PMID:
17554040
42.

A novel bis-tetrahydrofuranylurethane-containing nonpeptidic protease inhibitor (PI), GRL-98065, is potent against multiple-PI-resistant human immunodeficiency virus in vitro.

Amano M, Koh Y, Das D, Li J, Leschenko S, Wang YF, Boross PI, Weber IT, Ghosh AK, Mitsuya H.

Antimicrob Agents Chemother. 2007 Jun;51(6):2143-55. Epub 2007 Mar 19.

43.

Atomic resolution crystal structures of HIV-1 protease and mutants V82A and I84V with saquinavir.

Tie Y, Kovalevsky AY, Boross P, Wang YF, Ghosh AK, Tozser J, Harrison RW, Weber IT.

Proteins. 2007 Apr 1;67(1):232-42.

PMID:
17243183
44.

The complex role of Fcgamma receptors in the pathology of arthritis.

Boross P, Verbeek JS.

Springer Semin Immunopathol. 2006 Dec;28(4):339-50. Epub 2006 Oct 17. Review.

PMID:
17043867
45.

Effect of immune serum and role of individual Fcgamma receptors on the intracellular distribution and survival of Salmonella enterica serovar Typhimurium in murine macrophages.

Uppington H, Menager N, Boross P, Wood J, Sheppard M, Verbeek S, Mastroeni P.

Immunology. 2006 Oct;119(2):147-58. Epub 2006 Jul 12.

46.

Effect of mutations on the dimer stability and the pH optimum of the human foamy virus protease.

Sperka T, Boross P, Eizert H, Tözsér J, Bagossi P.

Protein Eng Des Sel. 2006 Aug;19(8):369-75. Epub 2006 Jun 24.

PMID:
16799151
47.

Structural and kinetic analysis of caspase-3 reveals role for s5 binding site in substrate recognition.

Fang B, Boross PI, Tozser J, Weber IT.

J Mol Biol. 2006 Jul 14;360(3):654-66. Epub 2006 Jun 2.

PMID:
16781734
48.

Characterization of the murine leukemia virus protease and its comparison with the human immunodeficiency virus type 1 protease.

Fehér A, Boross P, Sperka T, Miklóssy G, Kádas J, Bagossi P, Oroszlan S, Weber IT, Tözsér J.

J Gen Virol. 2006 May;87(Pt 5):1321-30.

PMID:
16603535
49.

Mechanism of drug resistance revealed by the crystal structure of the unliganded HIV-1 protease with F53L mutation.

Liu F, Kovalevsky AY, Louis JM, Boross PI, Wang YF, Harrison RW, Weber IT.

J Mol Biol. 2006 May 19;358(5):1191-9. Epub 2006 Mar 20.

PMID:
16569415
50.

Effectiveness of nonpeptide clinical inhibitor TMC-114 on HIV-1 protease with highly drug resistant mutations D30N, I50V, and L90M.

Kovalevsky AY, Tie Y, Liu F, Boross PI, Wang YF, Leshchenko S, Ghosh AK, Harrison RW, Weber IT.

J Med Chem. 2006 Feb 23;49(4):1379-87.

Supplemental Content

Loading ...
Support Center